Open access
Open access
Powered by Google Translator Translator

Chest Medicine (all articles)

Systematic Review: SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19.

23 Jun, 2022 | 10:37h | UTC

SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 – Cochrane Library

Summary: Are laboratory-made COVID-19-specific monoclonal antibodies effective to prevent COVID-19 in adults? – Cochrane Library

 


ASA and APSF statement on perioperative testing for the COVID-19 virus.

22 Jun, 2022 | 12:19h | UTC

ASA and APSF Statement on Perioperative Testing for the COVID-19 Virus – American Society of Anesthesiologists

Commentary: ASA, APST Update Perioperative SARS-CoV-2 Testing Recommendations – HealthDay

Related:

Surgical Triage and Timing for Patients with COVID: A Guidance Statement from the Society of Thoracic Surgeons – Annals of Thoracic Surgery

When to operate after SARS-CoV-2 infection? A review on the recent consensus recommendation of the DGC/BDC and the DGAI/BDA – Langenbeck’s Archives of Surgery

Guideline Update: Timing of elective surgery and risk assessment after SARS-CoV-2 infection – “The guidance remains that patients should avoid elective surgery within 7 weeks of infection, unless the benefits of doing so exceed the risk of waiting”.

Perioperative cardiovascular considerations prior to elective noncardiac surgery in patients with a history of Covid-19.

Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery

Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk

BJS commission on surgery and perioperative care post-COVID-19.

The risk of postoperative complications following major elective surgery in active or resolved COVID-19 in the United States – Major, elective surgery 0–4 weeks after Covid-19 is associated with greatly increased risk of postoperative complications; surgery performed 4–8 weeks after infection is still associated with an increased risk of pneumonia.

ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.

Position statement: Perioperative management of post-COVID-19 surgical patients.

Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19

 


Review: Sex differences in sequelae from COVID-19 infection and in long COVID syndrome.

22 Jun, 2022 | 12:06h | UTC

Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review – Current Medical Research and Opinion

Commentary: Women more likely to have long COVID, different symptom profile – CIDRAP

 


RCT: Efficacy and safety of varenicline for smoking cessation in patients with type 2 diabetes.

22 Jun, 2022 | 11:16h | UTC

Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Type 2 Diabetes: A Randomized Clinical Trial – JAMA Network Open

Author Interview: Efficacy and Safety of Varenicline in Patients With Type 2 Diabetes – JAMA

 

Commentary on Twitter

 


RCT: High-flow nasal cannula vs. conventional oxygen therapy in acute COPD exacerbation with mild hypercapnia.

22 Jun, 2022 | 11:09h | UTC

High-flow nasal cannula versus conventional oxygen therapy in acute COPD exacerbation with mild hypercapnia: a multicenter randomized controlled trial – Critical Care

 


Randomized cross-over study: closed-loop oxygen control improves oxygen therapy in acute hypoxemic respiratory failure patients under high flow nasal oxygen.

22 Jun, 2022 | 11:08h | UTC

Closed-loop oxygen control improves oxygen therapy in acute hypoxemic respiratory failure patients under high flow nasal oxygen: a randomized cross-over study (the HILOOP study) – Critical Care

 


RCT: Low-dose methylprednisolone does not improve outcomes in critically ill patients with severe community-acquired pneumonia.

21 Jun, 2022 | 11:04h | UTC

Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia – Intensive Care Medicine

 


How common is long COVID? Why studies give different answers.

21 Jun, 2022 | 11:03h | UTC

How common is long COVID? Why studies give different answers – Nature

 


WHO Interim statement on decision-making considerations for the use of variant updated COVID-19 vaccines.

20 Jun, 2022 | 10:42h | UTC

Interim statement on decision-making considerations for the use of variant updated COVID-19 vaccines – World Health Organization

See also: Interim statement on the composition of current COVID-19 vaccines – World Health Organization

 

Commentary on Twitter (thread – click for more)

 


Consensus Study: A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research.

20 Jun, 2022 | 10:31h | UTC

A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study – The Lancet Respiratory Medicine

News Release: Key outcomes of Long COVID identified in international consensus study – King’s College London

Invited Commentary: Post-COVID-19 condition in children: a COS is urgently needed – The Lancet Respiratory Medicine

 

Commentary on Twitter

 


Clues to long Covid: Scientists strive to unravel what is driving disabling symptoms.

20 Jun, 2022 | 10:30h | UTC

Clues To Long Covid – Science

 


Case-control study: Risk of long COVID associated with delta vs. omicron variants of SARS-CoV-2.

20 Jun, 2022 | 10:34h | UTC

Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2 – The Lancet

News Release: Long COVID risk less during Omicron compared to Delta, study finds – King’s College London

Commentaries:

Expert reaction to study looking at long COVID prevalence associated with delta versus omicron variants of SARS-CoV-2 – Science Media Centre

Omicron less likely to lead to long COVID, study finds – CIDRAP

Covid-19: Long covid risk is lower with omicron than delta, researchers find – The BMJ

 

Commentary on Twitter

 


[Preprint] Open-label RCT: Baricitinib noninferior to Tocilizumab in hospitalized patients with severe COVID-19.

20 Jun, 2022 | 10:28h | UTC

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial – medRxiv

Related:

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial – The Lancet Respiratory Medicine

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

WHO recommends two new drugs to treat COVID-19 – World Health Organization

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine

 

Commentary on Twitter

 


Brief Review: Helmet noninvasive support in hypoxemic respiratory failure.

20 Jun, 2022 | 01:13h | UTC

Helmet noninvasive support in hypoxemic respiratory failure – Intensive Care Medicine (if the link is paywalled, try this one)

 

Commentary on Twitter

 


#CCR22 – RCT: High-flow nasal cannula therapy met criteria for noninferiority compared to CPAP for the liberation from respiratory support in acutely ill children in the ICU.

16 Jun, 2022 | 11:10h | UTC

Effect of High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure Therapy on Liberation From Respiratory Support in Acutely Ill Children Admitted to Pediatric Critical Care Units: A Randomized Clinical Trial – JAMA (free for a limited period)

 

Commentary on Twitter

 


#CCR22 – RCT: Among critically ill patients undergoing tracheal intubation, administering a 500 ml fluid bolus did not decrease the incidence of severely low blood pressure, cardiac arrest, or death.

16 Jun, 2022 | 11:08h | UTC

Effect of Fluid Bolus Administration on Cardiovascular Collapse Among Critically Ill Patients Undergoing Tracheal Intubation: A Randomized Clinical Trial – JAMA (free for a limited period)

 

Commentary on Twitter

 


Perspective | Viruses that were on hiatus during Covid are back — and behaving in unexpected ways.

16 Jun, 2022 | 11:06h | UTC

Viruses that were on hiatus during Covid are back — and behaving in unexpected ways – STAT

 


Review: The physiological underpinnings of life-saving respiratory support.

16 Jun, 2022 | 11:03h | UTC

The physiological underpinnings of life-saving respiratory support – Intensive Care Medicine

 

Commentary on Twitter

 


Pfizer’s Paxlovid study fails to answer key questions over benefit for broader populations.

15 Jun, 2022 | 11:22h | UTC

Pfizer’s Paxlovid study fails to answer key questions over benefit for broader populations – STAT

 


RCT: Effect of varenicline added to counseling on smoking cessation among African American daily smokers.

15 Jun, 2022 | 11:18h | UTC

Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers: The Kick It at Swope IV Randomized Clinical Trial – JAMA Network Open

Editorial: Helping African American Individuals Quit Smoking: Finally, Some Progress – JAMA

News Release: Varenicline Increases Smoking Cessation Rates for African American Smokers – University of Kansas Cancer Center

 

Commentary on Twitter

 


Analysis of thromboembolic and thrombocytopenic events after the AstraZeneca, Pfizer, and Moderna COVID-19 vaccines in 3 Nordic countries.

15 Jun, 2022 | 11:17h | UTC

Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries – JAMA Network Open

 


M-A: Treatment outcomes among pregnant patients with multidrug-resistant tuberculosis.

15 Jun, 2022 | 10:47h | UTC

Treatment Outcomes Among Pregnant Patients With Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis – JAMA Network Open

 

Commentary on Twitter

 


Cohort Study | Intermediate-risk pulmonary embolism: echocardiography predictors of clinical deterioration.

15 Jun, 2022 | 10:34h | UTC

Intermediate-risk pulmonary embolism: echocardiography predictors of clinical deterioration – Critical Care

 


Systematic Review: Janus kinase inhibitors for the treatment of COVID‐19.

14 Jun, 2022 | 11:14h | UTC

Janus kinase inhibitors for the treatment of COVID‐19 – Cochrane Library

Summary: Are systemic Janus kinase inhibitors an effective treatment for people with COVID-19? – Cochrane Library

 


[Preprint] RCT: Ivermectin does not benefit patients with mild-to-moderate COVID-19 in the outpatient setting.

14 Jun, 2022 | 11:12h | UTC

Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial – medRxiv

Commentary: Study finds no benefit to taking ivermectin for COVID-19 symptoms – Duke University

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.